---
document_datetime: 2025-12-29 11:01:59
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/provenge.html
document_name: provenge.html
version: success
processing_time: 0.1057317
conversion_datetime: 2025-12-30 02:40:54.823421
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Provenge

[RSS](/en/individual-human-medicine.xml/66634)

##### Withdrawn

This medicine's authorisation has been withdrawn

autologous peripheral-blood mononuclear cells activated with prostatic acid phosphatase granulocyte-macrophage colony-stimulating factor (sipuleucel-T) Medicine Human Withdrawn

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Provenge](#news-on)
- [More information on Provenge](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 6 May 2015, the European Commission withdrew the marketing authorisation for Provenge (autologous peripheral blood mononuclear cells activated with PAP-GM-CSF (sipuleucel-T)) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Dendreon UK Ltd, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Provenge was granted marketing authorisation in the EU on 6 September 2013 for treating men with asymptomatic or minimally symptomatic metastatic (non-visceral) castrate-resistant prostate cancer in whom chemotherapy is not yet clinically indicated. The marketing authorisation was initially valid for a 5- year period.

The European Public Assessment Report (EPAR) for Provenge is updated accordingly to reflect the fact that the marketing authorisation is no longer valid.

Provenge : EPAR - Summary for the public

Reference Number: EMA/410890/2013

English (EN) (545.79 KB - PDF)

**First published:** 03/10/2013

**Last updated:** 19/05/2015

[View](/en/documents/overview/provenge-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-965)

български (BG) (628.86 KB - PDF)

**First published:**

03/10/2013

**Last updated:**

19/05/2015

[View](/bg/documents/overview/provenge-epar-summary-public_bg.pdf)

español (ES) (544.66 KB - PDF)

**First published:**

03/10/2013

**Last updated:**

19/05/2015

[View](/es/documents/overview/provenge-epar-summary-public_es.pdf)

čeština (CS) (610.2 KB - PDF)

**First published:**

03/10/2013

**Last updated:**

19/05/2015

[View](/cs/documents/overview/provenge-epar-summary-public_cs.pdf)

dansk (DA) (545 KB - PDF)

**First published:**

03/10/2013

**Last updated:**

19/05/2015

[View](/da/documents/overview/provenge-epar-summary-public_da.pdf)

Deutsch (DE) (573.84 KB - PDF)

**First published:**

03/10/2013

**Last updated:**

19/05/2015

[View](/de/documents/overview/provenge-epar-summary-public_de.pdf)

eesti keel (ET) (543.14 KB - PDF)

**First published:**

03/10/2013

**Last updated:**

19/05/2015

[View](/et/documents/overview/provenge-epar-summary-public_et.pdf)

ελληνικά (EL) (631.55 KB - PDF)

**First published:**

03/10/2013

**Last updated:**

19/05/2015

[View](/el/documents/overview/provenge-epar-summary-public_el.pdf)

français (FR) (551 KB - PDF)

**First published:**

03/10/2013

**Last updated:**

19/05/2015

[View](/fr/documents/overview/provenge-epar-summary-public_fr.pdf)

hrvatski (HR) (566.49 KB - PDF)

**First published:**

03/10/2013

**Last updated:**

19/05/2015

[View](/hr/documents/overview/provenge-epar-summary-public_hr.pdf)

italiano (IT) (543.38 KB - PDF)

**First published:**

03/10/2013

**Last updated:**

19/05/2015

[View](/it/documents/overview/provenge-epar-summary-public_it.pdf)

latviešu valoda (LV) (626.34 KB - PDF)

**First published:**

03/10/2013

**Last updated:**

19/05/2015

[View](/lv/documents/overview/provenge-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (570.71 KB - PDF)

**First published:**

03/10/2013

**Last updated:**

19/05/2015

[View](/lt/documents/overview/provenge-epar-summary-public_lt.pdf)

magyar (HU) (602.68 KB - PDF)

**First published:**

03/10/2013

**Last updated:**

19/05/2015

[View](/hu/documents/overview/provenge-epar-summary-public_hu.pdf)

Malti (MT) (613.34 KB - PDF)

**First published:**

03/10/2013

**Last updated:**

19/05/2015

[View](/mt/documents/overview/provenge-epar-summary-public_mt.pdf)

Nederlands (NL) (543.66 KB - PDF)

**First published:**

03/10/2013

**Last updated:**

19/05/2015

[View](/nl/documents/overview/provenge-epar-summary-public_nl.pdf)

polski (PL) (609.79 KB - PDF)

**First published:**

03/10/2013

**Last updated:**

19/05/2015

[View](/pl/documents/overview/provenge-epar-summary-public_pl.pdf)

português (PT) (544.41 KB - PDF)

**First published:**

03/10/2013

**Last updated:**

19/05/2015

[View](/pt/documents/overview/provenge-epar-summary-public_pt.pdf)

română (RO) (571.49 KB - PDF)

**First published:**

03/10/2013

**Last updated:**

19/05/2015

[View](/ro/documents/overview/provenge-epar-summary-public_ro.pdf)

slovenčina (SK) (610.13 KB - PDF)

**First published:**

03/10/2013

**Last updated:**

19/05/2015

[View](/sk/documents/overview/provenge-epar-summary-public_sk.pdf)

slovenščina (SL) (1.1 MB - PDF)

**First published:**

03/10/2013

**Last updated:**

19/05/2015

[View](/sl/documents/overview/provenge-epar-summary-public_sl.pdf)

Suomi (FI) (541.78 KB - PDF)

**First published:**

03/10/2013

**Last updated:**

19/05/2015

[View](/fi/documents/overview/provenge-epar-summary-public_fi.pdf)

svenska (SV) (544.4 KB - PDF)

**First published:**

03/10/2013

**Last updated:**

19/05/2015

[View](/sv/documents/overview/provenge-epar-summary-public_sv.pdf)

## Product information

Provenge : EPAR - Product Information

English (EN) (874.11 KB - PDF)

**First published:** 03/10/2013

**Last updated:** 19/05/2015

[View](/en/documents/product-information/provenge-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-832)

български (BG) (1.7 MB - PDF)

**First published:**

03/10/2013

**Last updated:**

19/05/2015

[View](/bg/documents/product-information/provenge-epar-product-information_bg.pdf)

español (ES) (897.93 KB - PDF)

**First published:**

03/10/2013

**Last updated:**

19/05/2015

[View](/es/documents/product-information/provenge-epar-product-information_es.pdf)

čeština (CS) (1.41 MB - PDF)

**First published:**

03/10/2013

**Last updated:**

19/05/2015

[View](/cs/documents/product-information/provenge-epar-product-information_cs.pdf)

dansk (DA) (883.3 KB - PDF)

**First published:**

03/10/2013

**Last updated:**

19/05/2015

[View](/da/documents/product-information/provenge-epar-product-information_da.pdf)

Deutsch (DE) (925.15 KB - PDF)

**First published:**

03/10/2013

**Last updated:**

19/05/2015

[View](/de/documents/product-information/provenge-epar-product-information_de.pdf)

eesti keel (ET) (874.85 KB - PDF)

**First published:**

03/10/2013

**Last updated:**

19/05/2015

[View](/et/documents/product-information/provenge-epar-product-information_et.pdf)

ελληνικά (EL) (1.72 MB - PDF)

**First published:**

03/10/2013

**Last updated:**

19/05/2015

[View](/el/documents/product-information/provenge-epar-product-information_el.pdf)

français (FR) (917.88 KB - PDF)

**First published:**

03/10/2013

**Last updated:**

19/05/2015

[View](/fr/documents/product-information/provenge-epar-product-information_fr.pdf)

hrvatski (HR) (1.03 MB - PDF)

**First published:**

03/10/2013

**Last updated:**

19/05/2015

[View](/hr/documents/product-information/provenge-epar-product-information_hr.pdf)

íslenska (IS) (944.48 KB - PDF)

**First published:**

03/10/2013

**Last updated:**

19/05/2015

[View](/is/documents/product-information/provenge-epar-product-information_is.pdf)

italiano (IT) (858.5 KB - PDF)

**First published:**

03/10/2013

**Last updated:**

19/05/2015

[View](/it/documents/product-information/provenge-epar-product-information_it.pdf)

latviešu valoda (LV) (1.45 MB - PDF)

**First published:**

03/10/2013

**Last updated:**

19/05/2015

[View](/lv/documents/product-information/provenge-epar-product-information_lv.pdf)

lietuvių kalba (LT) (990.83 KB - PDF)

**First published:**

03/10/2013

**Last updated:**

19/05/2015

[View](/lt/documents/product-information/provenge-epar-product-information_lt.pdf)

magyar (HU) (1.44 MB - PDF)

**First published:**

03/10/2013

**Last updated:**

19/05/2015

[View](/hu/documents/product-information/provenge-epar-product-information_hu.pdf)

Malti (MT) (1.46 MB - PDF)

**First published:**

03/10/2013

**Last updated:**

19/05/2015

[View](/mt/documents/product-information/provenge-epar-product-information_mt.pdf)

Nederlands (NL) (856.93 KB - PDF)

**First published:**

03/10/2013

**Last updated:**

19/05/2015

[View](/nl/documents/product-information/provenge-epar-product-information_nl.pdf)

norsk (NO) (876.08 KB - PDF)

**First published:**

03/10/2013

**Last updated:**

19/05/2015

[View](/no/documents/product-information/provenge-epar-product-information_no.pdf)

polski (PL) (1.45 MB - PDF)

**First published:**

03/10/2013

**Last updated:**

19/05/2015

[View](/pl/documents/product-information/provenge-epar-product-information_pl.pdf)

português (PT) (945.01 KB - PDF)

**First published:**

03/10/2013

**Last updated:**

19/05/2015

[View](/pt/documents/product-information/provenge-epar-product-information_pt.pdf)

română (RO) (1.01 MB - PDF)

**First published:**

03/10/2013

**Last updated:**

19/05/2015

[View](/ro/documents/product-information/provenge-epar-product-information_ro.pdf)

slovenčina (SK) (1.41 MB - PDF)

**First published:**

03/10/2013

**Last updated:**

19/05/2015

[View](/sk/documents/product-information/provenge-epar-product-information_sk.pdf)

slovenščina (SL) (1.45 MB - PDF)

**First published:**

03/10/2013

**Last updated:**

19/05/2015

[View](/sl/documents/product-information/provenge-epar-product-information_sl.pdf)

Suomi (FI) (934.22 KB - PDF)

**First published:**

03/10/2013

**Last updated:**

19/05/2015

[View](/fi/documents/product-information/provenge-epar-product-information_fi.pdf)

svenska (SV) (887.25 KB - PDF)

**First published:**

03/10/2013

**Last updated:**

19/05/2015

[View](/sv/documents/product-information/provenge-epar-product-information_sv.pdf)

06/05/2015

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Provenge : EPAR - All Authorised presentations

English (EN) (483.34 KB - PDF)

**First published:** 03/10/2013

**Last updated:** 19/05/2015

[View](/en/documents/all-authorised-presentations/provenge-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-656)

български (BG) (532.33 KB - PDF)

**First published:**

03/10/2013

**Last updated:**

19/05/2015

[View](/bg/documents/all-authorised-presentations/provenge-epar-all-authorised-presentations_bg.pdf)

español (ES) (484.74 KB - PDF)

**First published:**

03/10/2013

**Last updated:**

19/05/2015

[View](/es/documents/all-authorised-presentations/provenge-epar-all-authorised-presentations_es.pdf)

čeština (CS) (519.47 KB - PDF)

**First published:**

03/10/2013

**Last updated:**

19/05/2015

[View](/cs/documents/all-authorised-presentations/provenge-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (482.74 KB - PDF)

**First published:**

03/10/2013

**Last updated:**

19/05/2015

[View](/da/documents/all-authorised-presentations/provenge-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (482.78 KB - PDF)

**First published:**

03/10/2013

**Last updated:**

19/05/2015

[View](/de/documents/all-authorised-presentations/provenge-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (484.49 KB - PDF)

**First published:**

03/10/2013

**Last updated:**

19/05/2015

[View](/et/documents/all-authorised-presentations/provenge-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (529.06 KB - PDF)

**First published:**

03/10/2013

**Last updated:**

19/05/2015

[View](/el/documents/all-authorised-presentations/provenge-epar-all-authorised-presentations_el.pdf)

français (FR) (482.6 KB - PDF)

**First published:**

03/10/2013

**Last updated:**

19/05/2015

[View](/fr/documents/all-authorised-presentations/provenge-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (504.53 KB - PDF)

**First published:**

03/10/2013

**Last updated:**

19/05/2015

[View](/hr/documents/all-authorised-presentations/provenge-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (484.36 KB - PDF)

**First published:**

03/10/2013

**Last updated:**

19/05/2015

[View](/is/documents/all-authorised-presentations/provenge-epar-all-authorised-presentations_is.pdf)

italiano (IT) (482.69 KB - PDF)

**First published:**

03/10/2013

**Last updated:**

19/05/2015

[View](/it/documents/all-authorised-presentations/provenge-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (523.51 KB - PDF)

**First published:**

03/10/2013

**Last updated:**

19/05/2015

[View](/lv/documents/all-authorised-presentations/provenge-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (511.81 KB - PDF)

**First published:**

03/10/2013

**Last updated:**

19/05/2015

[View](/lt/documents/all-authorised-presentations/provenge-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (510.86 KB - PDF)

**First published:**

03/10/2013

**Last updated:**

19/05/2015

[View](/hu/documents/all-authorised-presentations/provenge-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (529.82 KB - PDF)

**First published:**

03/10/2013

**Last updated:**

19/05/2015

[View](/mt/documents/all-authorised-presentations/provenge-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (482.49 KB - PDF)

**First published:**

03/10/2013

**Last updated:**

19/05/2015

[View](/nl/documents/all-authorised-presentations/provenge-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (484.5 KB - PDF)

**First published:**

03/10/2013

**Last updated:**

19/05/2015

[View](/no/documents/all-authorised-presentations/provenge-epar-all-authorised-presentations_no.pdf)

polski (PL) (522.96 KB - PDF)

**First published:**

03/10/2013

**Last updated:**

19/05/2015

[View](/pl/documents/all-authorised-presentations/provenge-epar-all-authorised-presentations_pl.pdf)

português (PT) (482.87 KB - PDF)

**First published:**

03/10/2013

**Last updated:**

19/05/2015

[View](/pt/documents/all-authorised-presentations/provenge-epar-all-authorised-presentations_pt.pdf)

română (RO) (514.45 KB - PDF)

**First published:**

03/10/2013

**Last updated:**

19/05/2015

[View](/ro/documents/all-authorised-presentations/provenge-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (514.08 KB - PDF)

**First published:**

03/10/2013

**Last updated:**

19/05/2015

[View](/sk/documents/all-authorised-presentations/provenge-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (986.07 KB - PDF)

**First published:**

03/10/2013

**Last updated:**

19/05/2015

[View](/sl/documents/all-authorised-presentations/provenge-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (482.33 KB - PDF)

**First published:**

03/10/2013

**Last updated:**

19/05/2015

[View](/fi/documents/all-authorised-presentations/provenge-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (482.7 KB - PDF)

**First published:**

03/10/2013

**Last updated:**

19/05/2015

[View](/sv/documents/all-authorised-presentations/provenge-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Provenge Active substance autologous peripheral-blood mononuclear cells including a minimum of 50 million autologous CD54+ cells activated with prostatic acid phosphatase granulocyte-macrophage colony-stimulating factor International non-proprietary name (INN) or common name autologous peripheral-blood mononuclear cells activated with prostatic acid phosphatase granulocyte-macrophage colony-stimulating factor (sipuleucel-T) Therapeutic area (MeSH) Prostatic Neoplasms Anatomical therapeutic chemical (ATC) code L03AX17

### Pharmacotherapeutic group

Other immunostimulants

### Therapeutic indication

Provenge is indicated for treatment of asymptomatic or minimally symptomatic metastatic (non-visceral) castrate-resistant prostate cancer in male adults in whom chemotherapy is not yet clinically indicated.

## Authorisation details

EMA product number EMEA/H/C/002513

Advanced therapy

This medicine is classified as an advanced therapy medicinal product (ATMP): a medicine for human use that is based on genes, tissues or cells. It offers groundbreaking new opportunities for the treatment of disease and injury. For more information, see [Advanced therapy medicinal products: Overview](/node/69659) .

Marketing authorisation holder

Dendreon UK Ltd

41 Chalton Street

Marketing authorisation issued 06/09/2013 Withdrawal of marketing authorisation 06/05/2015 Revision 1

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Provenge : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (532.51 KB - PDF)

**First published:** 20/05/2015

**Last updated:** 20/05/2015

[View](/en/documents/procedural-steps-after/provenge-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Provenge : EPAR - Public assessment report

Adopted

Reference Number: EMA/440011/2013

English (EN) (4.12 MB - PDF)

**First published:** 03/10/2013

**Last updated:** 19/05/2015

[View](/en/documents/assessment-report/provenge-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Provenge

Adopted

Reference Number: EMA/CHMP/363851/2013

English (EN) (531.29 KB - PDF)

**First published:** 28/06/2013

**Last updated:** 19/05/2015

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-provenge_en.pdf)

#### News on Provenge

[European Medicines Agency recommends approval of 44 medicines for human use and six medicines for veterinary use in first half 2013](/en/news/european-medicines-agency-recommends-approval-44-medicines-human-use-six-medicines-veterinary-use-first-half-2013) 31/07/2013

[European Medicines Agency recommends approval of fourth advanced therapy in Europe](/en/news/european-medicines-agency-recommends-approval-fourth-advanced-therapy-europe) 28/06/2013

#### More information on Provenge

- [A Registry in the European Union of Provenge Therapy in Men with Metastatic Castrate-Resistant Prostate Cancer (START) - post-authorisation study](https://catalogues.ema.europa.eu/study/9783)

**This page was last updated on** 19/05/2015

## Share this page

[Back to top](#main-content)